Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate

Cancer

Volumn 80, Issue 11, 1997, Pages 2109-2119

  Theodorescu, Dan ^a   Broder, Stanford R ^a   Boyd, James C ^b   Mills, Stacey E ^b   Frierson Jr , Henry F ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Adenocarcinoma; Bcl 2; Follow up studies; P53; Prostate neoplasms; Retinoblastoma; Staging

Indexed keywords

CATHEPSIN D; CHROMOGRANIN A; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME;

CARCINOMA; CATHEPSIN D; CHROMOGRANIN A; CHROMOGRANINS; DISEASE-FREE SURVIVAL; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0030722145     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19971201)80:11<2109::AID-CNCR10>3.0.CO;2-2     Document Type: Article

References (38)

1. Epstein JI. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: prognostic influences of stage, tumor volume, grade, and margins of resection. Semin Oncol 1994;21:527-41.
2. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C) [see comments]. J Urol 1994;152:1721-9.
3. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests [see comments]. J Urol 1994;152:1714-20.
4. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA 1993;270:948-54.
5. Takayama TK, Vessella RL, Lange PH. Newer applications of serum prostate-specific antigen in the management of prostate cancer. Semin Oncol 1994;21:542-53.
6. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer [see comments]. J Urol 1994;152:1837-42.
7. Ellis WJ, Lange PH. Prostate cancer. Endocrinol Metab Clin North Am 1994;23:809-24.
8. Whittemore AS, Keller JB, Betensky R. Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? [see comments]. J Natl Cancer Inst 1991;83:1231-5.
9. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid H-P. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
10. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106-9.
11. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70:1252-7.
12. Noordzij MA, Van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995;62:252-8.
13. Allen FJ, Van Velden DJ, Heyns CF. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br J Urol 1995;75:751-4.
14. Aprikian AG, Cordon-Cardo C, Fair WR, Zhang ZF, Bazinet M, Hamdy SM, et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994;151:914-9.
15. Van de Voorde WM, Elgamal AA, Van Poppel HP, Verbeken EK, Baert LV, Lauweryns JM. Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies. Cancer 1994;74:3164-75.
16. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-7.
17. Moul JW, Maygarden SJ, Ware JL, Mohler JL, Maher PD, Schenkman NS, et al. Cathepsin D and epidermal growth factor receptor immunohistochemistry does not predict recurrence of prostate cancer in patients undergoing radical prostatectomy. J Urol 1996;155:982-5.
18. Conover CA, Perry JE, Tindall DJ. Endogenous cathepsin D-mediated hydrolysis of insulin-like growth factor-binding proteins in cultured human prostatic carcinoma cells. J Clin Endocrinol Metab 1995;80:987-93.
19. Ross JS, Nazeer T, Figge HL, Fisher HA, Rifkin MD. Quantitative immunohistochemical determination of cathepsin D levels in prostatic carcinoma biopsies. Correlation with tumor grade, stage, PSA level, and DNA ploidy status. Am J Clin Pathol 1995;104:36-41.
20. Chambon M, Rebillard X, Rochefort H, Brouillet JP, Baldet P, Guiter J, et al. Cathepsin D cytosolic assay and immunohistochemical quantification in human prostate tumors. Prostate 1994;24:320-5.
21. Makar R, Mason A, Kittelson JM, Bowden GT, Cress AE, Nagle RB. Immunohistochemical analysis of cathepsin D in prostate carcinoma. Mod Pathol 1994;7:747-51.
22. Maygarden SJ, Novotny DB, Moul JW, Bae VL, Ware JL. Evaluation of cathepsin D and epidermal growth factor receptor in prostate carcinoma. Mod Pathol 1994;7:930-6.
23. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells [see comments]. Hum Pathol 1995;26:167-70.
24. di Sant'Agnese PA, de Mesy Jensen KL. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987;18: 849-56.
25. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26:824-8.
26. Mills SE, Fowler JE, Jr. Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens. Cancer 1986;57:346-9.
27. Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol 1990; 21:799-804.
28. Cox DR. Partial likelihood. Biometrika 1975;62:269-79.
29. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc 1972;B34:187-220.
30. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-65.
32. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
33. Brawer MK, Beatie J, Wener MH, Vessella RL, Preston SD, Lange PH. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol 1993;150: 106-9.
34. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer [see comments]. J Urol 1993;150: 110-4.
35. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-68.
36. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-96.
37. Bologna M, Festuccia C, Muzi P, Biordi L, Ciomei M. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer 1989;63:1714-20.
38. Hoosein NM, Logothetis CJ, Chung LW. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells. J Urol 1993; 149:1209-13.